These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin. Minkutė R; Briedis V; Steponavičiūtė R; Vitkauskienė A; Mačiulaitis R J Clin Pharm Ther; 2013 Dec; 38(6):462-7. PubMed ID: 23924288 [TBL] [Abstract][Full Text] [Related]
85. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections]. Du B; Chen DC; Liu DW Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Jan; 15(1):32-4. PubMed ID: 12852813 [TBL] [Abstract][Full Text] [Related]
86. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. Vance-Bryan K; Rotschafer JC; Gilliland SS; Rodvold KA; Fitzgerald CM; Guay DR J Antimicrob Chemother; 1994 Apr; 33(4):811-21. PubMed ID: 8056700 [TBL] [Abstract][Full Text] [Related]
87. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis. Chen XY; Xu RX; Zhou X; Liu Y; Hu CY; Xie XF Int Urol Nephrol; 2018 Nov; 50(11):2019-2026. PubMed ID: 29752626 [TBL] [Abstract][Full Text] [Related]
88. Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center. Marquis KA; DeGrado JR; Labonville S; Kubiak DW; Szumita PM Ann Pharmacother; 2015 Sep; 49(9):1009-14. PubMed ID: 25991831 [TBL] [Abstract][Full Text] [Related]
89. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Kullar R; Davis SL; Taylor TN; Kaye KS; Rybak MJ Pharmacotherapy; 2012 Mar; 32(3):195-201. PubMed ID: 22392452 [TBL] [Abstract][Full Text] [Related]
90. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156 [TBL] [Abstract][Full Text] [Related]
91. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556 [TBL] [Abstract][Full Text] [Related]
92. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? Kralovicová K; Spanik S; Halko J; Netriova J; Studena-Mrazova M; Novotny J; Grausova S; Koren P; Krupova I; Demitrovicova A; Kukuckova E; Krcmery V J Chemother; 1997 Dec; 9(6):420-6. PubMed ID: 9491842 [TBL] [Abstract][Full Text] [Related]
93. Impact of piperacillin/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia. Hall RG; Yoo E; Faust A; Smith T; Goodman E; Mortensen EM; Raza J; Dehmami F; Alvarez CA Int J Antimicrob Agents; 2019 Mar; 53(3):343-346. PubMed ID: 30415001 [TBL] [Abstract][Full Text] [Related]
94. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721 [TBL] [Abstract][Full Text] [Related]
95. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis. Kullar R; McClellan I; Geriak M; Sakoulas G Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897 [TBL] [Abstract][Full Text] [Related]
96. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. McKamy S; Hernandez E; Jahng M; Moriwaki T; Deveikis A; Le J J Pediatr; 2011 Mar; 158(3):422-6. PubMed ID: 20888013 [TBL] [Abstract][Full Text] [Related]
97. Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion. Chambers ST; Long M; Gardiner SJ; Chin PKL; Yi M; Dalton SC; Drennan PG; Metcalf SCL Int J Antimicrob Agents; 2020 Jun; 55(6):105972. PubMed ID: 32298746 [TBL] [Abstract][Full Text] [Related]
98. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Nahata MC Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631 [TBL] [Abstract][Full Text] [Related]